The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences director and officer Cao Sean Wuxiong reported an open-market sale of ADSs tied to equity compensation. He sold 9,304 American Depositary Shares (ADSs), representing approximately 21,399 ordinary shares, at a price expressed in ADS terms of $1.99. According to the footnotes, this sale was made in connection with the partial vesting of a restricted stock unit award on January 31, 2026, solely to cover tax withholding obligations related to that vesting. Following the transaction, he holds 35,073 ordinary shares, represented by 15,249 ADSs, indicating this was a routine tax-related disposition rather than a full exit.
NovaBridge Biosciences officer Mark Arnold Hagler reported an open-market purchase of 230,000 Ordinary Shares, represented by 100,000 American Depositary Shares (ADSs). The weighted average purchase price was $2.51 per ADS, with individual trades between $2.44 and $2.54. Following the transaction, he directly holds 230,000 Ordinary Shares.
NovaBridge Biosciences filed an initial Form 3 for Hagler Mark Arnold, who is identified as an officer of the company with the title noted as “See Remarks.” The filing does not report any transactions or holdings, serving as an initial beneficial ownership statement.
NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer, effective April 17, 2026, adding senior commercial leadership as its oncology and ophthalmology pipeline advances. Hagler has more than 25 years of biopharma experience, including leading a $1 billion-plus portfolio and over 600 staff at Sun Pharmaceutical Industries.
He previously held senior roles at Ipsen, Sanofi, Novartis and Abraxis BioScience, helping launch key oncology drugs such as Abraxane and Afinitor. His commercial and pre-commercial expertise is expected to support NovaBridge’s mid-stage programs, including the Claudin 18.2 x 4-1BB bispecific antibody givastomig and the dual VEGF-A x ANG-2 inhibitor VIS-101, as they move toward pivotal and Phase 2b studies.
NovaBridge Biosciences executive Xu Cong Claire filed an amended Form 3 to correct a typographical error in her reported holdings. She is now shown as beneficially owning 284,266 Ordinary Shares, which are represented by 123,594 American Depositary Shares (ADSs). Each 10 ADSs correspond to 23 Ordinary Shares. The amendment states that all other information from the original Form 3 remains unchanged and does not report any new share purchases, sales, or option exercises.
NovaBridge Biosciences reported a larger full-year 2025 loss while strengthening its balance sheet and advancing two lead drug programs. The company posted a net loss attributable to NovaBridge of $46.3 million from continuing operations, compared with $22.2 million in 2024, as research and development spending more than doubled to $62.9 million, driven mainly by in‑process R&D for VIS‑101 and the Bridge Health acquisition. Administrative expenses were $31.4 million, slightly higher year over year.
Cash, cash equivalents and short‑term investments reached $210.8 million as of December 31, 2025, aided by a $61.7 million underwritten equity offering, and are expected to fund operations through 2028. The pipeline is led by givastomig, a Claudin 18.2 × 4‑1BB bispecific antibody for first‑line gastric cancer, which showed a 75% objective response rate and 16.9‑month median progression‑free survival in Phase 1b, and has potential eligibility for the FDA’s Accelerated Approval Pathway with a registrational Phase 3 trial targeted as early as late 2026. VIS‑101, a VEGF‑A × ANG‑2 inhibitor for wet age‑related macular degeneration, delivered rapid, durable responses in Phase 2a with roughly half of treatment‑naïve patients remaining retreatment‑free at six months, and is planned to enter Phase 2b in the second half of 2026.
NovaBridge Biosciences, a Cayman Islands holding company focused on precision immuno-oncology and ophthalmology, reports that it had 265,377,891 ordinary shares outstanding as of December 31, 2025. The company divested its Greater China assets in April 2024 for contingent consideration of up to $80 million tied to future milestones and royalties, and now operates primarily through U.S. and limited PRC subsidiaries.
NovaBridge remains a clinical-stage company with no approved products and recorded net losses of $88.3 million in 2025. It held $210.8 million in cash, cash equivalents and short-term investments, which it believes will fund operations into the fourth quarter of 2028. Management highlights reliance on additional financing, complex PRC regulatory risks, HFCAA-related audit considerations, material weaknesses in IT general controls and a 27% workforce reduction under a 2025 realignment plan as key risk factors for investors.
NovaBridge Biosciences director Yang Conor Chia-hung filed an initial ownership report showing two employee stock option positions tied to the company’s Ordinary Shares. One 2024 option covers 114,093 underlying Ordinary Shares at an exercise price of $1.22 per ADS-equivalent, expiring on October 1, 2034, and is fully vested and exercisable. A 2025 option covers 34,530 underlying Ordinary Shares at an exercise price of $3.86 per ADS-equivalent, expiring on October 1, 2035, and will vest in full on the first anniversary of its October 1, 2025 grant date. Footnotes note that the Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares.
NovaBridge Biosciences officer Chu Denny Hsueh Wen filed a Form 3 as an officer of the company. The filing lists no reportable transactions, with buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring counts all shown as zero in this excerpt.